~~<i id='1B4AFBF4BE'><strike id='1B4AFBF4BE'><tt id='1B4AFBF4BE'><pre id='1B4AFBF4BE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：entertainment 2025-09-29 21:14:41 - browse：64599

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The EU Joint Clinical Assessment needs to live up to its promise

hotspot

leisure time

hotspot

leisure time

Anartist'srenderingofthebuilding—currentlyunderconstructionalongBoston'sFortPointChannel—whereEliLil

WSS

Beam Therapeutics to lay off 20% of its staff, re

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

STAT Summit: Michael J. Fox on progress in Parkinson's research

With psoriasis trial ahead, Alumis raises $259 million

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Will Ozempic

explore

explore

hotspot

Cancer drug shortages should be causing more outrage

FDA warns J&J's Abiomed: We will regulate your software

Psychedelics group wrestles with new pharma identity

NIH confirmation hearing shows politicization of research

FDA approval of Sarepta Duchenne genetic therapy gives me hope

A deep dive into Applied Therapeutics’ data, and questions on Cassava

ChatGPT in medicine: STAT answers readers' burning questions

IVF, abortion rights issues kick off Biden’s State of the Union

Sports medicine is finally prioritizing gender equality

Lawmakers consider Medicare pay reforms for doctors

leisure time

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

A deep dive into Applied Therapeutics’ data, and questions on Cassava

HHS leader on health, climate change and biopharma emissions

Amylyx ALS drug fails large clinical trial

The drug industry has found itself all alone in Washington

leisure time

hotspot

hotspot

leisure time